Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.
- Status
- enrolling by invitation
- Phase
- Phase 1
- Institution
- Centre for Addiction and Mental Health
- Principal investigator
- Gwyneth Zai, MD, MSc, PhD
- Start date
- 2024-09-01
- End date
- 2026-08-01
- Registry ID
- NCT06299319
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.